Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis.
Brivaracetam
Comorbidity
Effectiveness
Etiology
Real world
Tolerability
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
received:
11
12
2023
accepted:
10
02
2024
revised:
31
01
2024
medline:
4
3
2024
pubmed:
4
3
2024
entrez:
4
3
2024
Statut:
aheadofprint
Résumé
To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies. EXPERIENCE/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3 months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Analyses were performed for all adult patients (≥ 16 years of age) and stratified by comorbidity and by etiology at baseline (patients with cognitive/learning disability [CLD], psychiatric comorbidity, post-stroke epilepsy, brain tumor-related epilepsy [BTRE], and traumatic brain injury-related epilepsy [TBIE]). At 12 months, ≥ 50% seizure reduction was achieved in 35.6% (n = 264), 38.7% (n = 310), 41.7% (n = 24), 34.1% (n = 41), and 50.0% (n = 28) of patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, respectively; and continuous seizure freedom was achieved in 5.7% (n = 318), 13.7% (n = 424), 29.4% (n = 34), 11.4% (n = 44), and 13.8% (n = 29), respectively. During the study follow-up, in patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, 37.1% (n = 403), 30.7% (n = 605), 33.3% (n = 51), 39.7% (n = 68), and 27.1% (n = 49) of patients discontinued BRV, respectively; and TEAEs since prior visit at 12 months were reported in 11.3% (n = 283), 10.0% (n = 410), 16.7% (n = 36), 12.5% (n = 48), and 3.0% (n = 33), respectively. BRV as prescribed in the real world is effective and well tolerated among patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE.
Identifiants
pubmed: 38436680
doi: 10.1007/s00415-024-12253-z
pii: 10.1007/s00415-024-12253-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342:314–319. https://doi.org/10.1056/NEJM200002033420503
doi: 10.1056/NEJM200002033420503
Asadi-Pooya AA, Beniczky S, Rubboli G, Sperling MR, Rampp S, Perucca E (2020) A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. Epilepsia 61:1668–1677. https://doi.org/10.1111/epi.16610
doi: 10.1111/epi.16610
Doerrfuss JI, Kowski AB, Holtkamp M (2021) Etiology-specific response to antiseizure medication in focal epilepsy. Epilepsia 62:2133–2141. https://doi.org/10.1111/epi.17017
doi: 10.1111/epi.17017
Domínguez-Aguilera MC, Muñiz-Landeros CE (2017) Prevalence of psychiatric disorders in patients with epilepsy in a tertiary level care hospital: Detection through the MINI PLUS International Structured Interview. Medicina Universitaria 19:3–6. https://doi.org/10.1016/j.rmu.2016.11.003
doi: 10.1016/j.rmu.2016.11.003
Novak A, Vizjak K, Rakusa M (2022) Cognitive Impairment in People with Epilepsy. J Clin Med 11:267 https://doi.org/10.3390/jcm11010267
doi: 10.3390/jcm11010267
Mula M, Coleman H, Wilson SJ (2022) Neuropsychiatric and Cognitive Comorbidities in Epilepsy. Continuum (Minneap Minn) 28:457–482. https://doi.org/10.1212/con.0000000000001123
doi: 10.1212/con.0000000000001123
Eddy CM, Rickards HE, Cavanna AE (2011) The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord 4:385–407. https://doi.org/10.1177/1756285611417920
doi: 10.1177/1756285611417920
Mula M, Kanner AM, Jetté N, Sander JW (2021) Psychiatric Comorbidities in People With Epilepsy. Neurol Clin Pract 11:e112–e120. https://doi.org/10.1212/CPJ.0000000000000874
doi: 10.1212/CPJ.0000000000000874
Besag FMC (2004) Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf 3:1–8. https://doi.org/10.1517/14740338.3.1.1
doi: 10.1517/14740338.3.1.1
Schmitz B (2006) Effects of antiepileptic drugs on mood and behavior. Epilepsia 47:28–33. https://doi.org/10.1111/j.1528-1167.2006.00684.x
doi: 10.1111/j.1528-1167.2006.00684.x
Kanner AM (2016) Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol 12:106–116. https://doi.org/10.1038/nrneurol.2015.243
doi: 10.1038/nrneurol.2015.243
Balestrini S, Arzimanoglou A, Blümcke I et al (2021) The aetiologies of epilepsy. Epileptic Disord 23:1–16. https://doi.org/10.1684/epd.2021.1255
doi: 10.1684/epd.2021.1255
Galovic M, Ferreira-Atuesta C, Abraira L et al (2021) Seizures and Epilepsy After Stroke: Epidemiology, Biomarkers and Management. Drugs Aging 38:285–299. https://doi.org/10.1007/s40266-021-00837-7
doi: 10.1007/s40266-021-00837-7
Seidel S, Wehner T, Miller D, Wellmer J, Schlegel U, Grönheit W (2022) Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication. Neurol Res Pract 4:45. https://doi.org/10.1186/s42466-022-00205-9
doi: 10.1186/s42466-022-00205-9
Zimmermann LL, Martin RM, Girgis F (2017) Treatment options for posttraumatic epilepsy. Curr Opin Neurol 30:580–586. https://doi.org/10.1097/wco.0000000000000505
doi: 10.1097/wco.0000000000000505
Lucke-Wold BP, Nguyen L, Turner RC et al (2015) Traumatic brain injury and epilepsy: Underlying mechanisms leading to seizure. Seizure 33:13–23. https://doi.org/10.1016/j.seizure.2015.10.002
doi: 10.1016/j.seizure.2015.10.002
Verellen RM, Cavazos JE (2010) Post-traumatic epilepsy: an overview. Therapy 7:527–531. https://doi.org/10.2217/thy.10.57
doi: 10.2217/thy.10.57
Villanueva V, Laloyaux C, D’Souza W et al (2023) Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records. CNS Drugs 37:819–835. https://doi.org/10.1007/s40263-023-01033-4
doi: 10.1007/s40263-023-01033-4
Fisher RS, Cross JH, French JA et al (2017) Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE commission for Classification and Terminology. Epilepsia 58:522–530. https://doi.org/10.1111/epi.13670
doi: 10.1111/epi.13670
Therapeutic Goods Administration (2017) Product Information: Briviact. https://www.tga.gov.au/sites/default/files/auspar-brivaracetam-170307-pi-01.pdf . Accessed 5 Sep 2023
European Medicines Agency (2023) Briviact
US Food and Drug Administration (2023) BRIVIACT
Vacher E, Rodriguez Ruiz M, Rees JH (2023) Management of brain tumour related epilepsy (BTRE): a narrative review and therapy recommendations. Br J Neurosurg. https://doi.org/10.1080/02688697.2023.2170326
doi: 10.1080/02688697.2023.2170326
Foo EC, Geldard J, Peacey C, Wright E, Eltayeb K, Maguire M (2019) Adjunctive brivaracetam in focal and generalized epilepsies: a single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability. Epilepsy Behav 99:106505. https://doi.org/10.1016/j.yebeh.2019.106505
doi: 10.1016/j.yebeh.2019.106505
Andres E, Kerling F, Hamer H, Winterholler M (2018) Behavioural changes in patients with intellectual disability treated with brivaracetam. Acta Neurol Scand 138:195–202. https://doi.org/10.1111/ane.12943
doi: 10.1111/ane.12943
Meador KJ, Gevins A, Leese PT, Otoul C, Loring DW (2011) Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. Epilepsia 52:264–272. https://doi.org/10.1111/j.1528-1167.2010.02746.x
doi: 10.1111/j.1528-1167.2010.02746.x
Stephen LJ, Wishart A, Brodie MJ (2017) Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. Epilepsy Behav 71:73–78. https://doi.org/10.1016/j.yebeh.2017.04.003
doi: 10.1016/j.yebeh.2017.04.003
Willems LM, van der Goten M, von Podewils F et al (2023) Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy. CNS Drugs 37:531–544. https://doi.org/10.1007/s40263-023-01013-8
doi: 10.1007/s40263-023-01013-8
Arboix A (2015) Cardiovascular risk factors for acute stroke: Risk profiles in the different subtypes of ischemic stroke. World J Clin Cases 3:418–429. https://doi.org/10.12998/wjcc.v3.i5.418
doi: 10.12998/wjcc.v3.i5.418
Chohan SA, Venkatesh PK, How CH (2019) Long-term complications of stroke and secondary prevention: an overview for primary care physicians. Singapore Med J 60:616–620. https://doi.org/10.11622/smedj.2019158
doi: 10.11622/smedj.2019158
Atella V, Piano Mortari A, Kopinska J et al (2019) Trends in age-related disease burden and healthcare utilization. Aging Cell 18:e12861. https://doi.org/10.1111/acel.12861
doi: 10.1111/acel.12861
Public Health Agency of Canada (2020) Aging and chronic diseases. A profile of Canadian seniors. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/aging-chronic-diseases-profile-canadian-seniors-report.html . Accessed 29 Mar 2023
Semah F, Picot MC, Adam C et al (1998) Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 51:1256–1262. https://doi.org/10.1212/wnl.51.5.1256
doi: 10.1212/wnl.51.5.1256
Lattanzi S, Canafoglia L, Canevini MP et al (2022) Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Seizure 97:37–42. https://doi.org/10.1016/j.seizure.2022.03.007
doi: 10.1016/j.seizure.2022.03.007
Rizzo A, Donzelli S, Girgenti V et al (2017) In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells. J Exp Clin Cancer Res 36:76. https://doi.org/10.1186/s13046-017-0546-9
doi: 10.1186/s13046-017-0546-9
Maschio M, Maialetti A, Mocellini C et al (2020) Effect of Brivaracetam on Efficacy and Tolerability in Patients with Brain Tumor-Related Epilepsy: A Retrospective Multicenter Study. Front Neurol 11:813. https://doi.org/10.3389/fneur.2020.00813
doi: 10.3389/fneur.2020.00813